March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in 2025, the U.S. Food and Drug Administration (FDA) approved Ozempic ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Send comments and news tips to news@medscape.net. Cite this: Ozempic Receives New Indications in Chronic Kidney Disease - Medscape - January 29, 2025.

The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease.

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis (US ...

In the US, 1 in 7 adults are experiencing some type of chronic kidney disease caused by diabetes. The new approval therefore allows doctor to prescribe Ozempic to lower the risk of kidney failure ...

The Kidney Disease: Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday ...

Obesity does not only put individuals at risk for heart disease and diabetes—it's also a leading cause of kidney stone disease. Kidney stone disease is increasingly recognized as a chronic condition ...

Too often, patients with chronic kidney disease get diagnosed too late – if at all. Addressing risk factors early can stave off the disease’s worst effects.